人工智能模型在多中心真实世界DLBCL人群中分类CAR-T细胞治疗后早期复发风险
研究基于2017至2024年416例接受阿基仑赛治疗的成人DLBCL患者,评估真实世界疗效并开发决策树机器学习模型识别6个月内早期复发风险。模型基于年龄和6项常规实验室检查,受试者工作特征曲线下面积达0.82,决策曲线分析显示在0至0.7的决策阈值范围内有正向净获益。
要点
- 416例接受阿基仑赛的DLBCL患者中位无进展生存期10.1个月,中位总生存期54.4个月。
- 18个月无进展生存率和总生存率分别为41.6%和65.5%。
- 基于年龄和6项常规实验室检查的机器学习模型识别6个月内早期复发,AUC为0.82。
核心结论
- 本研究进一步证实了阿基仑赛在多样化人群中的真实世界表现。
- 机器学习模型为识别可能从额外干预中获益以延长生存结局的患者提供了新方法。
- 经前瞻性验证研究后,该模型和决策树方法可能支持高危DLBCL患者的临床决策。
研究设计与样本
- 多中心真实世界研究,纳入2017年至2024年间接受阿基仑赛治疗的416例成人弥漫性大B细胞淋巴瘤患者。
- 采用自动化计算方法评估阿基仑赛的真实世界表现,并开发决策树机器学习模型识别6个月内早期复发风险。
主要发现
- 中位无进展生存期为10.1个月,中位总生存期为54.4个月。
- 18个月无进展生存率为41.6%,18个月总生存率为65.5%。
- 严重细胞因子释放综合征发生率为18.8%,严重免疫效应细胞相关神经毒性综合征发生率为32.5%。
- 机器学习模型依赖年龄和6项常规实验室检查(乳酸脱氢酶、C反应蛋白、铁蛋白、血细胞比容、血小板计数和凝血酶原时间),受试者工作特征曲线下面积达0.82。
- 决策曲线分析显示模型在0至0.7的广泛决策阈值范围内具有正向净获益。
关键数值与推荐
- 机器学习模型受试者工作特征曲线下面积为0.82。
- 决策曲线分析显示在0至0.7的决策阈值范围内有正向净获益。
临床怎么用
- 经前瞻性验证研究后,该模型和决策树方法可能支持高危DLBCL患者的临床决策。
局限性
- 模型需经前瞻性验证研究后方可能支持临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accumulating real-world (RW) evidence of axicabtagene ciloleucel (axi-cel) has demonstrated comparable performance to that of pivotal trials. However, ∼57% of patients eventually relapse, with most requiring additional therapies. Being able to identify patients with risk of early relapse enables clinicians to consider additional interventions to extend survival outcomes. This study aimed to first comprehensively evaluate the RW performance of axi-cel in the multicenter University of California Health Systems using automated computational approaches. Second, we developed a decision tree machine learning (ML) model to identify patients with risks of early relapse within 6 months. A total of 416 adult patients with diffuse large B-cell lymphoma (DLBCL) receiving axi-cel between 2017 and 2024 were included in the study. The median progression-free survival (PFS) and overall survival (OS) were 10.1 and 54.4 months; the 18-month PFS and OS rates were 41.6% and 65.5%, respectively. Severe CRS and ICANS were observed in 18.8% and 32.5% of patients. The ML model, relying on age and 6 routinely measured laboratory tests (lactate dehydrogenase, C-reactive protein, ferritin, hematocrit, platelet count, and prothrombin time), achieved a high area under the receiver operating characteristic curve score of 0.82. The decision curve analysis indicated positive net benefit of the model across a broad range (0-0.7) of decision thresholds, suggesting clinical utility in diverse scenarios. This study further confirmed the RW performance of axi-cel in diverse populations. Our ML model represented a novel approach to identify patients that may benefit from additional interventions to extend survival outcomes. Following prospective confirmation study, our model and decision tree approach may support clinical decision making in patients with high-risk DLBCL.
引用
- Wang M, Komanduri KV, Datta D, et al. An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL. Blood Adv. 2025. PMID: 40902085. doi:10.1182/bloodadvances.2025016375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。